Joseph Haas

Type: Person
Name: Joseph Haas
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

SMITHS : John Crane Awarded Patent for Gas Seal Monitoring Technology

By a News Reporter-Staff News Editor at Journal of Technology -- The U.S. and European patent offices have awarded John Crane a patent for a breakthrough technology that will monitor the condition of a gas seal to improve product performance, extend average ... [Published 4 Traders - Mar 20 2014]
First reported Mar 10 2014 - Updated Mar 10 2014 - 1 reports

John Crane Awarded Patent for Gas Seal Monitoring Technology

10:00 AM Eastern Daylight TimeReflects continued investment in new technology and potential totransform $8 billion gas seal industryCHICAGO--( BUSINESS WIRE )-- The U.S. and European patent offices have awarded John Crane a patentfor a breakthrough technology ... [Published Business Wire - Mar 10 2014]
First reported Mar 07 2014 - Updated Mar 08 2014 - 1 reports

What Is the Buoyant Biotech IPO Scene Doing to Private Biotech M&A Trends? FOTF Says: Not Much

Despite a slight slowdown, there's considerable cash already sloshing around the biotech IPO space. There's (still!) plenty more stacked up in investor suitcases from California to the New York Island just waiting to back anything with a pulse. The ... [Published The IN VIVO Blog - Mar 07 2014]
First reported Feb 28 2014 - Updated Feb 28 2014 - 1 reports

DOTW Keeps Tabs As Tax Trimming Fuels Deals

As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ... [Published The IN VIVO Blog - Feb 28 2014]
First reported Feb 21 2014 - Updated Feb 21 2014 - 1 reports

Financings of the Fortnight And the Neverending Venture Round

Somewhere out there, perhaps, is the end of NovImmune's Series B round.More than a year ago, our friends at START-UP examined the fates of biotechs that had reeled in huge private financing rounds. Giant biotech venture rounds are back with a buzz ... [Published The IN VIVO Blog - Feb 21 2014]
Entities: NovImmune SA, IPOs, Argos
First reported Feb 14 2014 - Updated Feb 14 2014 - 1 reports

Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector

Neither MedImmune, the biologics arm of AstraZeneca, or the University of California, San Francisco, is a stranger to R&D collaboration between private industry and academia, but the agreement they signed on Feb. 11 is somewhat unique in that it ... [Published The IN VIVO Blog - Feb 14 2014]
First reported Feb 07 2014 - Updated Feb 07 2014 - 1 reports

Can Novel-Novel Combinations Work? Deals Of The Week Watches Merck Test The Waters

Merck & Co. Inc.’s Feb. 5 announcement that it is collaborating with three companies to test various combinations of its investigational oncology compound MK-3475 with their drugs highlights the extent to which the big pharma is committed to building ... [Published The IN VIVO Blog - Feb 07 2014]

More Content

All (7) | News (2) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
SMITHS : John Crane Awarded Patent for Gas Seal... [Published 4 Traders - Mar 20 2014]
John Crane Awarded Patent for Gas Seal Monitori... [Published Business Wire - Mar 10 2014]
What Is the Buoyant Biotech IPO Scene Doing to ... [Published The IN VIVO Blog - Mar 07 2014]
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
Deals Of The Week: UCSF Catalyzes R&D Tech-Tran... [Published The IN VIVO Blog - Feb 14 2014]
Can Novel-Novel Combinations Work? Deals Of The... [Published The IN VIVO Blog - Feb 07 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
What Is the Buoyant Biotech IPO Scene Doing to ... [Published The IN VIVO Blog - Mar 07 2014]
Despite a slight slowdown, there's considerable cash already sloshing around the biotech IPO space. There's (still!) plenty more stacked up in investor suitcases from California to the New York Island just waiting to back anything with a pulse. The ...
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ...
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
Somewhere out there, perhaps, is the end of NovImmune's Series B round.More than a year ago, our friends at START-UP examined the fates of biotechs that had reeled in huge private financing rounds. Giant biotech venture rounds are back with a buzz ...
Deals Of The Week: UCSF Catalyzes R&D Tech-Tran... [Published The IN VIVO Blog - Feb 14 2014]
Neither MedImmune, the biologics arm of AstraZeneca, or the University of California, San Francisco, is a stranger to R&D collaboration between private industry and academia, but the agreement they signed on Feb. 11 is somewhat unique in that it ...
Can Novel-Novel Combinations Work? Deals Of The... [Published The IN VIVO Blog - Feb 07 2014]
Merck & Co. Inc.’s Feb. 5 announcement that it is collaborating with three companies to test various combinations of its investigational oncology compound MK-3475 with their drugs highlights the extent to which the big pharma is committed to building ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.